Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID

Horizon Pharma plc

, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/596,919 (U.S. publication number 2015-0126607), entitled "Diclofenac Topical Formulation" that covers Horizon's U.S. approved product PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire in 2027. After issuance, Horizon plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the tenth U.S. patent to be listed in the Orange Book for PENNSAID 2%.